How Fast Can I Lose Weight with Wegovy?

Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a GLP-1 receptor agonist that slows stomach emptying and reduces hunger signals in the brain, leading to lower calorie intake and weight loss. Clinical trials show most people lose 5-15% of body weight within the first six months, though the exact timeline depends on your starting point, dose progression, and how your body responds to the medication.

Expected Weight Loss Timeline During the First Month

Most semaglutide users begin on a low starting dose to allow their body to adjust and minimize side effects. During the first month, many people report reduced appetite and early appetite suppression, but visible weight loss may be modest—typically 1-3 pounds. This initial phase is about establishing tolerance and beginning dose escalation rather than dramatic fat loss.

The first four weeks set the foundation for faster results later. Your digestive system adapts to slower gastric emptying, and hunger-regulating hormones begin shifting. Some users notice clothing fitting differently or energy levels changing before the scale reflects significant weight loss. Consistency with injections and adherence to lower-calorie eating patterns during this phase creates momentum for months ahead.

Weeks 5-12: When Noticeable Weight Loss Typically Appears

Between weeks 5 and 12, semaglutide doses usually reach therapeutic levels for appetite suppression. This is when most users observe consistent weekly weight loss of 1-2 pounds, totaling 4-8 pounds by the end of the second and third months. The medication's full appetite-suppressing effects become more pronounced, making calorie reduction feel natural rather than forced through willpower alone.

Clinical evidence from Novo Nordisk trials showed that by week 12, participants on semaglutide had lost approximately 6-8% of baseline body weight on average. Individual results vary significantly—some people lose faster, others more gradually—depending on starting weight, metabolic rate, and how well their body's GLP-1 receptors respond to the compound. This three-month checkpoint is often when patients feel confident that the medication is working.

Months 4-6: Peak Weight Loss and Dose Stabilization

Months four through six represent the period of maximum weight loss for many semaglutide users. Most reach their target maintenance dose by month three, and with the medication fully effective, average weekly loss continues at 1-2 pounds. Over this three-month span, additional weight loss of 3-6 pounds is common, bringing total loss to 10-20 pounds or roughly 5-15% of starting body weight by month six.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Factors That Affect Your Personal Weight Loss Timeline

Individual variation in semaglutide response is significant and influenced by multiple factors beyond the medication itself. Starting body weight, age, metabolic rate, concurrent health conditions, physical activity level, and baseline calorie intake all shape how quickly you lose weight. Someone starting at 280 pounds typically loses weight faster initially than someone at 200 pounds due to higher baseline metabolic demand.

Genetic factors also play a substantial role. Variants in the FTO, MC4R, and GIPR genes affect how strongly your body responds to semaglutide and how easily your metabolism maintains weight loss. PlexusDx maps 14 metabolic pathways and analyzes 150+ genetic insights through the Precision Peptide Genetic Test, allowing your provider to understand whether genetic predispositions support faster or more gradual weight loss patterns. Lifestyle factors—sleep quality, stress levels, dietary composition, and exercise consistency—magnify or diminish medication effects significantly.

Beyond Six Months: Weight Loss Plateau and Maintenance

After six months on semaglutide, many users experience a weight loss plateau where the rate of decline slows. This is normal physiology—as your body adapts to lower weight, metabolic rate adjusts downward, and the same calorie deficit produces smaller weekly losses. Some users plateau entirely while maintaining their achieved weight loss, while others continue gradual loss through month 12 and beyond.

Long-term success depends on sustaining healthy eating patterns and physical activity even as weight loss slows. Semaglutide continues reducing appetite, but continued discipline with food choices remains essential. Clinical data shows that people who maintain the medication alongside lifestyle changes preserve weight loss better than those who stop treatment. PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan with no flat per-compound pricing changes, making it accessible for long-term weight management without financial penalties as your dose stabilizes.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose in three months with semaglutide?

Most users lose 5-10% of their body weight by the three-month mark, which translates to roughly 10-25 pounds depending on starting weight. Results vary based on dose progression, adherence, diet quality, and individual metabolism. By month three, doses usually reach therapeutic levels where appetite suppression becomes pronounced.

Why do some people lose weight faster than others on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Is semaglutide from PlexusDx the same as Wegovy?

PlexusDx compounds semaglutide in licensed 503A pharmacies as a prescription-strength injectable, similar in composition to Wegovy but sourced differently and priced from $149 per month with no flat per-compound pricing increases. Your dose may go up, but your price won't. Both deliver the same active ingredient and produce comparable weight loss results.

What if I'm not losing weight as fast as expected?

Slower-than-expected weight loss can signal several factors: insufficient dose escalation, inconsistent injection adherence, high daily calorie intake, or genetic predispositions to slower response. Work with your PlexusDx provider to review these variables. Some users benefit from the Precision Peptide Genetic Test to understand metabolic pathway activity and optimize treatment timing and lifestyle interventions.

Will my weight loss continue indefinitely or does it eventually plateau?

Most users experience continued weight loss for 6-12 months before plateauing as their body adapts to lower weight and metabolic rate adjusts downward. Plateaus are normal and don't indicate medication failure—they represent your body reaching a new equilibrium. Continuing semaglutide helps maintain achieved weight loss better than discontinuing treatment.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.